帕尼培南倍他米隆的临床评价

Clinical evaluation of panipenem betamipron

目的 评价碳青霉烯类新药帕尼培南 倍他米隆的疗效与安全性。方法 以亚胺培南 西司他丁为对照药 ,对两种药物治疗重症下呼吸道、尿路和腹腔细菌性感染共 2 46例的疗效和安全性进行随机对照观察。另以帕尼培南 倍他米隆开放治疗其他感染 10例。结果 帕尼培南 倍他米隆组和亚胺培南 西司他丁组的有效率分别为 89 0 % (113/ 12 7)和 89 9% (10 7/ 119) ,细菌清除率分别为78 4% (98/ 12 5 )和 80 0 % (10 0 / 12 5 ) ;治疗组和对照组的不良反应发生率各为 5 8% (8/ 137)和 9 3%(12 / 12 9) ,所致实验室检查异常各占 5 8% (8/ 137)和 3 9% (5 / 12 8)。上述结果经统计学处理 ,两组差异均无显著性。 10例开放病例 8例痊愈 ,2例进步。结论 帕尼培南 倍他米隆治疗重症下呼吸道、尿路和腹腔等细菌性感染疗效确切且安全。

Objective To evaluate the efficacy and safety of panipenem betamipron, a new carbapenem. Methods A randomized controlled study of panipenem betamipron vs imipenem cilastatin in the treatment of 246 patients with severe bacterial infection of lower respiratory tract, urinary tract and abdomen was carried out. Panipenem betamipron was also administered non comparatively to 10 patients with septicemia and infection of central nervous system. Results The total effective rates of panipenem betamipron and imipenem cilastatin were 89.0% (113/127) and 89.9% (107/119), and bacterial eradication rates were 78.4% (98/125) and 80.0%(100/125), respectively. Adverse reaction rates of panipenem betamipron and imipenem cilastatin were 5.8% (8/137) and 9.3%(12/129), and the rates of laboratory abnormality caused by the two drugs were 5.8%(8/137) and 3.9%(5/128). There was no significant statistical difference between the two groups. The clinical response of non comparative cases was cure in 8 and improvement in 2. Conclusion Panipenem betamipron is effective and safe in the treating severe infections of lower respiratory tract, urinary tract and abdomen.